The laser system, launched in 2007, is used in more than 120 countries worldwide in laser vision correction procedures, including LASIK and surface ablation.

Alphaeon CEO Robert E Grant noted Rolf Schwind and his management team have continued to innovate and advance laser technology to give people the best vision possible.

"The speed of their laser system and integration of wavefront and topographic data have led to impressive clinical outcomes internationally, and we believe the AMARIS system will represent leading-edge technology for lifestyle patients seeking vision correction.

"Each of the product and software transactions completed in the past 90 days fits seamlessly into ALPHAEON’s strategy to lead the lifestyle healthcare market," Grant added.

Published data representing more than 10,000 eyes has demonstrated that 97% of all nearsighted patients treated with the AMARIS system achieved 20/20 or better unaided distance vision, when measured three months following treatment.

As part of the relationship, Alphaeon will oversee the US Food and Drug Administration (FDA) clinical trial required to market the product in the US.

Alphaeon’s licensing of the Schwind AMARIS excimer laser system marks the second ophthalmic licensing transaction and fifth overall transaction announced by the company since its corporate launch in July 2013.

In August, Alphaeon acquired the exclusive license to Teoxane Laboratories’ full portfolio of next-generation dermal fillers and cosmeceuticals, followed in October with the exclusive license to market EVOSYAL, an advanced neurotoxin.

In mid-October Alphaeon acquired the exclusive right to market TouchMD, a premier practice development platform and the Visiometrics S.L., HD Analyzer, the first early cataract detection device.

Alphaeon will begin commercializing products and services in January 2014.